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Comprehensive microRNA 
profiling in acetaminophen 
toxicity identifies novel circulating 
biomarkers for human liver and 
kidney injury
A. D. B. Vliegenthart1, J. M. Shaffer2, J. I. Clarke3, L. E. J. Peeters1, A. Caporali1, 
D. N. Bateman1, D. M. Wood4,5, P. I. Dargan4,5, D. G. Craig6, J. K. Moore6, A. I. Thompson7, 
N. C. Henderson7, D. J. Webb1, J. Sharkey3, D. J. Antoine3, B. K. Park3, M. A. Bailey1, 
E. Lader2, K. J. Simpson6 & J. W. Dear1
Our objective was to identify microRNA (miRNA) biomarkers of drug-induced liver and kidney injury 
by profiling the circulating miRNome in patients with acetaminophen overdose. Plasma miRNAs 
were quantified in age- and sex-matched overdose patients with (N = 27) and without (N = 27) organ 
injury (APAP-TOX and APAP-no TOX, respectively). Classifier miRNAs were tested in a separate 
cohort (N = 81). miRNA specificity was determined in non-acetaminophen liver injury and murine 
models. Sensitivity was tested by stratification of patients at hospital presentation (N = 67). From 
1809 miRNAs, 75 were 3-fold or more increased and 46 were 3-fold or more decreased with APAP-
TOX. A 16 miRNA classifier model accurately diagnosed APAP-TOX in the test cohort. In humans, 
the miRNAs with the largest increase (miR-122-5p, miR-885-5p, miR-151a-3p) and the highest rank 
in the classifier model (miR-382-5p) accurately reported non-acetaminophen liver injury and were 
unaffected by kidney injury. miR-122-5p was more sensitive than ALT for reporting liver injury at 
hospital presentation, especially combined with miR-483-3p. A miRNA panel was associated with 
human kidney dysfunction. In mice, miR-122-5p, miR-151a-3p and miR-382-5p specifically reported 
APAP toxicity - being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity 
identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced 
kidney injury.
Acetaminophen (paracetamol) is a safe analgesic drug when taken at therapeutic doses. However, in 
overdose acetaminophen is hepatotoxic and is the most common cause of acute liver failure in the United 
States and Europe1,2. After overdose, the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) 
is generated in excess, depleting cellular glutathione (GSH) then binding covalently to cellular pro-
teins resulting in oxidative stress and hepatocyte death, predominately by necrosis3. Cell death releases 
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intra-cellular molecules into the extra-cellular milieu and this is reflected by changes in circulating pro-
tein and RNA4. The current antidote, acetylcysteine (NAC), replenishes cellular GSH and is highly effec-
tive at preventing liver injury if administered soon after overdose5. However, NAC treatment takes at 
least 21 hours to complete so resulting in substantial hospital bed occupancy and commonly producing 
adverse drug reactions; 65% of NAC-treated patients vomited, retched or needed antiemetic therapy in 
a recent randomised controlled trial6. To selectively target treatment to those who stand to benefit and 
facilitate early safe hospital discharge of low risk patients there is an unmet need for new biomarkers 
that stratify patients by their risk of liver injury at first presentation to hospital, soon after overdose, an 
early time point when current markers such as serum alanine transaminase (ALT) activity lack sensitivity 
and specificity7.
Acetaminophen can also induce kidney tubular cell death resulting in acute kidney injury (AKI)8 and, 
in the presence of liver injury, AKI is one of the key predictors of need for urgent liver transplantation to 
avoid death. Kidney injury is currently quantified by serum creatinine. However, patients with AKI are 
not in steady-state with regard to kidney function and serum creatinine is slow to report cellular damage. 
Serum creatinine also lacks specificity, becoming elevated by non-renal pathologies such as dehydration 
and muscle injury9. New biomarkers are needed to report drug-induced kidney injury with enhanced 
sensitivity and specificity.
MicroRNAs (miRNAs) are small (~22 nucleotide-long) non-protein coding RNA species involved in 
post-transcriptional gene-product regulation10. In blood, miRNAs are stable because they are protected 
from degradation by extra-cellular vesicles (such as exosomes), RNA binding protein complexes (such as 
argonaute 2 – Ago2) and high-density lipoproteins11,12. The different circulating carriers for miRNA may 
reflect different pathways of release from cells; exosomal miRNAs may represent physiological release 
whereas miRNAs bound to Ago2 are increased with cell necrosis. As they are amplifiable and some are 
tissue restricted, miRNAs represent a reservoir for biomarker discovery. Liver-enriched miR-122-5p is 
released by injured hepatocytes and is a circulating biomarker for liver toxicity in zebrafish13, rodents14 
and humans15. In patients with acetaminophen-induced liver injury circulating miR-122-5p has been 
reported to be increased around 100-fold compared to controls15,16. However, it is not known whether 
other miRNAs can out-perform miR-122-5p with regard to patient stratification.
The field of profiling multiple circulating miRNAs to discover signatures of toxicity is relatively new. 
In rodent models of acetaminophen toxicity there have been profiling studies of relatively small num-
bers of circulating miRNAs - these studies demonstrate that multiple miRNA species change with liver 
injury17,18. In humans, a miRNome subset of 372 miRNAs was quantified in 49 patients with acetami-
nophen hepatotoxicity or ischemic hepatitis17. This study confirmed that miRNAs were increased and 
decreased and suggested that certain species could distinguish between these distinct aetiologies of liver 
injury17. Changes in circulating miRNAs have also been reported in small numbers of hepatotoxicity 
patients analysed by high-throughput sequencing18,19. These studies did not address the unmet clinical 
need for improved patient stratification, back translate to pre-clinical models or identify signals of kidney 
toxicity. In the present study we recruited over 200 patients and assayed miRBase version 18 to identify 
which miRNAs were differentially expressed in plasma from overdose patients with and without aceta-
minophen toxicity (APAP-TOX and APAP-no TOX, respectively). Selected miRNA candidate biomarkers 
were tested for liver and kidney specificity in humans and mice, and sensitivity with regard to patient 
stratification at first presentation to hospital.
Results
Circulating miRNAs that were differentially expressed with acute liver injury. The experi-
mental design used to identify differentially expressed miRNAs is presented in Fig. 1. In phase 1 of this 
discovery study, randomly selected APAP-TOX and APAP-no TOX samples were pooled and expressed 
miRNAs were identified. From 1809 miRNA species, 359 miRNAs fulfilled our criteria of expression (Ct 
value < 35 with a single, sharp melt peak) in at least one of the 4 sample pools (2 x APAP-TOX and 2 x 
APAP-no TOX). The patient demographics and clinical chemistry results from APAP-TOX and APAP-no 
TOX patients in the training set and test set are presented in supplementary Table 1. In Phase II, these 
359 miRNAs were quantified in each of the 54 patient samples of the training set using a bespoke PCR 
array. The PCR results from phase II for each microRNA are presented in supplementary file 1. The PCR 
results from 1 sample in the APAP-TOX group did not have any amplification curves and this sample 
was excluded from further analyses. The phase II PCR profiling results: 75 miRNAs were 3-fold or more 
increased in the APAP-TOX patient group compared to the age- and sex-matched APAP-no TOX group. 
46 miRNAs were 3-fold or more decreased in the APAP-TOX patient group. These data are presented 
in Fig. 2A as a volcano plot. The largest median (IQR) increased circulating miRNAs were miR-122-5p 
68 (11–277), miR-885-5p 57 (17–372) and miR-151a-3p 57 (16–360) (Fig.  2B). A heatmap with clus-
ter analysis of > 3-fold increased/decreased circulating miRNAs in the APAP-no TOX and APAP-TOX 
patients from the training set is displayed in supplementary Figure 1. This heatmap demonstrates that 
APAP-TOX patients can be clustered into sub-groups based on the expression of miRNA panels. There 
was a group of patients with lower miR-30b-5p, miR-186-5p, miR-382-5p, miR-27a-3p, miR-15a-3p and 
miR15a-5p. These APAP-TOX patients were more unwell (INR 2.0 (16-3.4) v 1.4 (1.2–1.5) in rest of 
APAP-Tox group P = 0.003; serum creatinine 152 mg/dl (64–289) v 61 mg/dl (58–67) P = 0.01). The larg-
est fold increase miRNAs (miR-122-5p and miR-885-5p) were highly correlated across patients in the 
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training set (Fig. 3A). miR-122-5p has been reported to circulate in a protein fraction of plasma rather 
than in extra-cellular vesicles although this has not been characterized in humans. After antibody-medi-
ated pull down of Ago2 (corrected by IgG control), acetaminophen toxicity induced a significant increase 
in the amount of miR-122-5p and miR-885-5p specifically bound to Ago2 (Fig.  3B,C), consistent with 
both miRNAs being released bound to this protein. Interestingly there was no increase in miR-151a-3p, 
which suggests different mechanisms of release across miRNA species (Fig.  3D). In situ hybridization 
for miR-122-5p and miR-885-5p was performed on liver explants removed following acetaminophen 
overdose. Both these miRNAs localised to hepatocytes and their expression was reduced in the areas of 
centrilobular necrosis, consistent with release from injured cells (Fig. 3E).
Development and testing of miRNA diagnostic panels. In Phase III random forest statistics were 
used to identify which miRNAs separate APAP-TOX from APAP-no TOX. The analysis demonstrated 
that 16 miRNAs (‘classifier model’) had the lowest prediction error - the largest marginal decrease in 
prediction accuracy when their values are randomly permuted (Fig. 4A). This classifier model was tested 
in an independent test set of 81 patient samples (Fig.  4B). The probability of a sample being correctly 
classified by the miRNA model as APAP-TOX was significantly higher when the true classification was 
APAP-TOX (median percent probability (IQR): 75 (63–77) for true APAP-TOX; 44 (43–47) for true 
APAP-no TOX; P < 0.0001). For an APAP-TOX classification probability cut-off of 50% (i.e. higher prob-
ability of APAP-TOX than APAP-no TOX) the classifier series sensitivity was 90% (95% CI: 76 to 97) 
and specificity was 90% (77 to 97) (Fig. 4B).
Specificity of candidate miRNA biomarkers. The 3 largest fold increase miRNAs (miR-122-5p, 
miR-885-5p and miR-151a-3p) and the miRNA with the lowest prediction error from the classifier model 
(miR-382-5p) were taken forward and tested for specificity and sensitivity.
Human specificity studies. In patients with acute liver injury (ALI) due to a diverse range of 
non-acetaminophen causes, all 4 miRNA species were significantly changed in their circulating 
Figure 1. Study design. Phase I identified the expressed microRNAs (miRNAs) in pooled samples from 
acetaminophen toxicity (APAP-TOX) patients and acetaminophen overdose with no toxicity (APAP-no 
TOX) patients. In Phase II, expressed miRNAs were quantified in 27 APAP-TOX and 27 APAP-no TOX 
patients. For data processing, Ct values were calibrated for RNA recovery using the cel-miR-39-3p assay 
(which detects a synthetic miRNA spiked in to each sample during sample prep). In Phase III, random forest 
analysis was performed to develop the classifier model that was subsequently tested in the test set.
www.nature.com/scientificreports/
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concentration to levels comparable with the APAP-TOX group (Fig.  5A–D). The kidney is commonly 
injured in the setting of ALI so could be the tissue of origin for circulating miRNAs and kidney dysfunc-
tion could affect the circulating concentration of liver-derived miRNAs by altering their clearance. Two 
complementary approaches were used to determine miRNA liver specificity in the presence of kidney 
Figure 2. Differentially expressed circulating microRNAs (miRNAs) with toxicity. (A) Volcano plot of 
miRNA data when acetaminophen toxicity (APAP-TOX) patients were compared with age and sex matched 
acetaminophen no toxicity (APAP-no TOX) patients. The negative logarithm base 10 of the P-value is 
plotted against log 2 difference in estimated relative expression values. Respectively, the triangles and squares 
correspond to miRNAs that were more than 3 fold increased or decreased in the APAP-TOX patients 
relative to the APAP-no TOX patients. (B) Box-and-whisker plots displaying the top 15 highest fold increase 
miRNAs and 5 highest fold decrease miRNAs. The fold regulation was calculated using the 2−ΔΔCt method. 
Statistically significant differences were determined by Wilcoxon matched-pairs signed rank test using 2−ΔCt. 
Ct values were normalized using global Ct mean. Statistically significant differences were determined by 
Mann Whitney Test using Δ Ct values. ***P < 0.001; **P < 0.01; *P < 0.05.
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injury. APAP-TOX patients without and with kidney dysfunction (serum creatinine concentration 
> 110 μ mol/L) were compared across the training and test sets (supplementary Table 2). There was an 
increase in the median PCR-array Ct value with kidney dysfunction, consistent with a overall reduction 
Figure 3. miR-122-5p and miR-885-5p are released from human hepatocytes bound to the carrier 
protein Ago2. Figure (A) Pearson correlation plot of circulating miR-885-5p and miR-122-5p across APAP-
TOX and APAP-no TOX patients. Figure (B–D) represent the relative Ago2 fraction for miR-122-5p, miR-
885-5p and miR-151a-5p respectively in APAP-TOX (N = 6) and APAP-no TOX (N = 6) patients. The Y axis 
represents the 2−ΔCt value obtained from the Ago2 pull-down minus the 2−ΔCt value obtained from the IgG 
pull-down from the same sample, both normalised by spiked-in synthetic miR-39. Statistically significant 
differences were determined by Mann Whitney Test. Figure (E) presents liver tissue from 2 patients whom 
underwent liver transplantation for severe acute liver failure due to acetaminophen overdose. Images from 
hematoxylin and eosin (H&E) and in situ hybridization for miR-122-5p and miR-885-5p are presented.
www.nature.com/scientificreports/
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in circulating miRNAs (APAP-TOX no AKI: 16.55 (15.78–17.49); APAP-TOX AKI: 18.01 (16.84–19.02). 
P = 0.0007). However, there was no difference in miR-122-5p, miR-885-5p, miR-151a-3p or miR-382-5p 
(Table 1). The miRNAs that were significantly changed with kidney dysfunction are presented in Table 1.
Mouse specificity studies. Mouse models of acetaminophen and cisplatin toxicity were compared 
with regard to miRNA circulating concentrations, cisplatin toxicity being a well-established model of 
drug-induced AKI. Acetaminophen induced liver injury was confirmed by a median (IQR) serum ALT 
activity of 7230IU/L (5355–23615, N = 8) and histologically by centrilobular hepatic necrosis. By contrast 
with vehicle treated controls (N = 7), acetaminophen toxicity in mice resulted in increased miR-122-5p 
and miR-151a-3p, and decreased miR-382-5p, in line with our human data (Fig. 5E–H). However, miR-
885-5p was not translatable across species and did not change. Cisplatin-induced AKI was demonstrated 
by significant elevations in urinary KIM-1 concentration (control: 1322 pg/mgUCr (766–1460); cisplatin 
10,964 pg/mgUCr (4493–16003). N = 7, P = 0.0003) and histologically, there were apoptotic proximal 
tubular cells, sloughing and an overall reduced number of epithelial cells. Cisplatin had no effect on 
miR-122-5p, miR-885-5p, miR-151a-3p or miR-382-5p (Fig. 5E–H).
Human case report. To further define temporal changes, miRNA candidate biomarkers were measured 
in serial samples from a 49 year-old man who presented to hospital soon after a large overdose (4 hour 
acetaminophen concentration: 405 mg/L) with initially normal serum ALT activity (28 U/L) and kidney 
function (serum creatinine: 83 μ mol/L). Despite prompt NAC treatment (started 6 hours after overdose), 
the patient subsequently developed significant liver injury (peak ALT: 12,353 U/L) with coagulopathy 
(peak INR: 2.8) and kidney injury (peak creatinine: 151 μ mol/L) (Fig. 6F–H). The patient’s liver injury 
recovered with continued NAC treatment, providing an opportunity to track miRNA concentrations 
from no apparent injury, into significant organ injury and through to liver recovery. The temporal pro-
files of the individual miRNAs were different; miR-122-5p concentration was elevated but decreased 
earlier than ALT (Fig. 6A). miR-885-5p remained elevated longer than miR-122-5p (Fig. 6B). In line with 
the array data, both miR-382-5p and miR-19a substantially decreased in concentration and, interestingly, 
they remained below the hospital admission level (Fig. 6C,D). miR-34a initially increased but then fell 
to below the admission concentration, a decrease which corresponded temporally with increased serum 
creatinine concentration (Fig. 6E).
Identification of endogenous miRNA normalizers. To identify which miRNAs were most stably 
expressed across APAP-TOX and APAP-no TOX patients NormFinder analysis was performed on the 
training set data. miR-1287 was the most stably expressed with a stability value of 1.22*10− 5. All results 
from the NormFinder assessment are reported in supplementary Table 3. miR-1913, miR-671, miR-1287, 
Let-7d, miR-1260 and miR-324 were taken forward and measured in the APAP-early patient samples 
using RT-PCR. The demographics and standard clinical chemistry for this patient cohort are presented 
in supplementary Table 4. In accordance with the NormFinder assessment, miR-1287 was most stably 
expressed across the different samples with a coefficient of variation (CV) of 1.71% (supplementary 
Figure 2).
Sensitivity - comparison of leading microRNA discriminators with ALT as a diagnostic of early 
ALI. In the 67 APAP-early patients, miR-122-5p identified subsequent liver injury when normalized by 
BA
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Figure 4. Random forest statistics analysis. Figure (A) presents the top 16 miRNAs that separate APAP-
TOX from APAP-no TOX in the training set. miRNAs were ranked according to the marginal decrease in 
out-of-bag prediction accuracy when the gene’s expression measurements are scrambled. Figure (B) Receiver 
operator characteristic curve displaying the performance of the top 16 miRNAs from the training set with 
regard to distinguishing APAP-TOX from APAP- no TOX in the test set.
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any of the 6 endogenous miRNA normalizers described above (miR-122-5p area under ROC curve nor-
malized by miR-1913, 0.97 (95% CI 0.92–1.01); miR-671, 0.96 (0.92–1.01); miR-1287, 0.95 (0.90–1.00); 
let7-d, 0.94 (0.89–1.00); miR-1260, 0.93 (0.88–1.00); miR-324, 0.93 (0.87–1.00) miR-122-5p ROC-AUC 
significantly larger than all other miRNAs – P < 0.05). miR-885-5p, miR-151a-5p and miR-382-5p were 
inferior to ALT for early prediction of liver injury (Fig. 7). When the largest fold increase and decrease 
phase II miRNAs were combined (miR-122-5p and miR-483-3p, respectively) there was a modest increase 
in the area under the ROC curve compared with miR-122-5p alone. No other miRNA combination 
improved predictive accuracy (data not shown).
Discussion
To date, this is the largest and most comprehensive study of the circulating miRNome in humans with 
acetaminophen toxicity. We identified multiple miRNA species that separated APAP-TOX from APAP-no 
TOX in a training set of patients, then tested the panels in a separate patient cohort. The large number of 
Figure 5. Biomarker specificity for liver injury. Figure (A–D) present circulating miR-122-5p, miR-885-5p, 
miR-151a-3p and miR-382-5p in APAP-no TOX patients and patients with acute liver injury (ALI) induced 
by APAP overdose or another aetiology (non-APAP). Figure (E–H) present miR-122-5p, miR-885-5p, miR-
151a-3p and miR-382-5p in control mice, APAP overdose mice and cisplatin-induced acute kidney injury 
(AKI) mice. Values represent 2−ΔCt normalised by miR-1287 in human samples and spiked in synthetic miR-
39 in mice samples. Statistically significant differences were determined by Wilcoxon matched-pairs signed 
rank test.
miRNA
Fold 
change P value
ROC-AUC (95% 
CI) P value SENS (95% CI)
miR-19a-3p − 3.76 <0.0001 0.76 (0.66–0.86) <0.0001 0.51 (0.35–0.67)
miR-19b-3p − 4.10 0.001 0.73 (0.61–0.85) 0.001 0.27 (0.12–0.46)
miR-192-5p − 1.66 0.001 0.73 (0.61–0.85) 0.001 0.20 (0.08–0.39)
miR-34a-5p − 5.71 0.003 0.71 (0.58–0.83) 0.003 0.20 (0.08–0.39)
miR-3187-3p − 5.30 0.005 0.70 (0.58–0.83) 0.005 0.47 (0.28–0.66)
miR-122-5p 1.28 0.92 0.51 (0.36–0.65) 0.92 0.27 (0.12–0.46)
miR-885-5p 1.25 0.73 0.53 (0.38–0.67) 0.72 0.33 (0.17–0.53)
miR-151a-3p 1.28 0.27 0.58 (0.44–0.72) 0.27 0.10 (0.02–0.27)
miR-382-5p 1.46 0.67 0.53 (0.39–0.68) 0.67 0.17 (0.06–0.35)
Table 1.  Comparison of circulating miRNAs in acetaminophen-induced acute liver injury patients with 
and without kidney dysfunction. ROC-AUC (area under the curve with 95% CI), sensitivity (SENS with 
95% CI) at 90% specificity and statistical significance are given. Negative fold change means lower with 
kidney dysfunction.
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miRNAs that were screened in this study (1809) allowed the identification of novel miRNA species that 
report toxicity. The largest fold change miRNAs (miR-122-5p, miR-885-5p and miR-151-3p) and the best 
discriminating miRNA (miR-382-5p) were taken forward and tested for specificity. Although variable, 
they report acute liver injury across patients and mouse models, even in the presence of kidney injury. 
Kidney injury resulted in significantly decreased miRNAs that represent new circulating biomarker can-
didates. The most stable internal miRNA normalizers were discovered and used to normalize miRNAs 
to compare with ALT activity with regard to sensitivity (the stratification of patients at first presentation 
to hospital). miR-122-5p very accurately predicted liver injury at first presentation to hospital, especially 
when combined with the largest decrease miRNA.
This study reported that 75 circulating miRNA species were more than 3-fold increased with acute 
liver injury, demonstrating the potential of multiple miRNA species as biomarkers. miRNAs identified 
in the training set of patients were validated in a separate patient cohort from a separate clinical unit. 
This 16-miRNA ‘signature’ of acute liver injury accurately identified toxicity. The most abundant miRNA 
Figure 6. Timeline of current and novel miRNA biomarkers following a large acetaminophen overdose 
in a 49 year-old male. Values for miRNA represent 2−ΔCt normalised by spiked-in synthetic miR-39.
www.nature.com/scientificreports/
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species in the liver20, miR-122-5p, was the highest increased circulating miRNA but other species were 
elevated to comparable degrees (miR-885-5p, miR-151-3p) or were ranked higher by random forest anal-
ysis in terms of ability to report injury (miR-382-5p). Circulating miRNAs are stable because they are 
either bound to proteins or encapsulated in extra-cellular vesicles (or both). The presence of miRNA in 
vesicles such as exosomes is controversial, with some studies reporting very low amounts in the exosomal 
cargo21. Also extra-cellular vesicles contain Ago2 suggesting there is not a clear division between the two 
circulating fractions. For the first time we demonstrate that human miR-122-5p circulates bound to the 
protein Ago2 and this fraction increases with liver injury. Ago2-bound miR-885-5p also increases with 
injury and both these miRNAs were localised to hepatocytes by in situ hybridization on human liver 
explants removed at transplantation for acetaminophen toxicity. These data suggest release of miR-122 
and miR-885 from the same cells attached to the same carrier protein.
The 3 highest fold increase miRNAs and the leading discriminator in our model were tested for 
specificity. Across all our human array studies and in mice models miR-382-5p decreased in circulating 
Figure 7. Biomarker sensitivity - ROC curve analysis supports the potential for miR-122-5p to predict 
the development of ALI. ROC analysis was calculated to determine the potential for plasma miRNAs 
and serum ALT activity to predict the development of TOX at first presentation to hospital following 
acetaminophen overdose. TOX was defined as > 3xULN ALT activity during hospital admission. The ROC 
curves of the 4 most accurate predictors are presented. AUC (area under the curve with 95% CI), sensitivity 
(SENS at 90% specificity) with 95% CI, positive and negative predictive values (PPV and NPV) and 
statistical significance for AUC value is presented in table. The miRNAs are normalized by miR-1287.
www.nature.com/scientificreports/
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concentration with liver injury. The mechanism of this circulating decrease of miR-382-5p is unknown, 
but conceptually could be either a decrease in production (such as reduced gene transcription in the 
injured liver) or increased clearance. Given that more miRNAs increase than decrease in the circula-
tion with acute liver injury it would require a highly selective process of altered clearance to explain 
the specific decrease in miR-382-5p and decreased tissue expression seems more plausible. miR-122-5p, 
miR-885-5p, miR-151-3p and miR-382-5p reported acute liver injury due to causes other than acetami-
nophen, which is consistent with them being liver specific and demonstrates that this panel has utility 
in the diagnosis of acute liver injury due to multiple causes. Furthermore, none of this panel changed 
with kidney injury in humans or mice, which also supports liver specificity and validates their use in 
patients with liver and kidney injury, which commonly co-exist in life-threatening acute liver failure. 
There were miRNA species that changed with kidney dysfunction and they consistently decreased in cir-
culating concentration. A general fall in circulating miRNA concentrations has been reported in chronic 
kidney disease and suggested to be due increased blood RNAase activity22. Our data would suggest AKI 
also reduces most, but not all, circulating miRNAs. In the present study the performance of the lead-
ing miRNA, miR-19a, was modest with regard to separating liver injury from liver and kidney injury 
(ROC-AUC 0.76). However, human diagnostic performance may be improved when multiple time points 
post-drug exposure are analysed in larger studies. This is supported by the case reported in this paper, 
which demonstrated a decrease in miR-19a before serum creatinine was elevated. By definition, the 
patients with kidney dysfunction had more severe acetaminophen toxicity and differences in circulating 
miRNAs could reflect more severe liver injury rather than kidney injury per se. Whether miRNA species 
such as miR-19a are truly kidney specific or represent liver toxicity prognosis markers is an important 
area for further development.
It is widely reported that miRNAs translate across species; for example, we have reported that miR-
122-5p reports liver injury in cell models, zebrafish, rodents and humans. Our array data are consistent 
with smaller acetaminophen studies performed in rodents: 586 miRNA species were measured in mice14 
and 750 miRNA species were measured in rats23. In addition to miR-122-5p, the miRNA species miR-22, 
miR-29b, miR-29c, miR-130a and miR-193 were increased in both mice and humans. In rats, in addition 
to miR-122-5p, the increase of miR-22, miR-193 and miR-194 was in accordance with our human data23. 
This demonstrates the translational potential of miRNAs across rodents and humans. However, the data 
presented in this study clearly demonstrate that miR-885-5p does not increase with acetaminophen tox-
icity in mice, an important limitation. Comparative biomarker profiles for miR-122-5p, miR-885-5p, 
miR-151-3p and miR-382-5p are summarized in supplementary Table 5.
Although miR-122-5p had the highest fold increase in APAP-TOX patients, it was ranked 11th place 
in the miRNA panel, suggesting that other microRNA species may have greater clinical utility. As a first 
step in determining the clinical utility of our miRNA panel, the performance of selected members was 
compared with ALT with regard to patient stratification at first presentation to the ED. These patients 
were recruited from a different hospital to the training and test patient sets (London as compared to 
Edinburgh). ROC analysis revealed that miR-122-5p was superior to ALT activity with regard to pre-
dicting APAP-TOX in early APAP patients. This observation confirms our previous investigation, in 
which miR-122-5p displayed superior predictive value over ALT activity at the hospital ‘front door’, in a 
separate cohort of patients from a different hospital16. miRNA species were identified which were stable 
across patients with and without organ injury. These internal normalizers can be used to report sample 
degradation and failed miRNA extraction from plasma. Therefore, they are of value for future studies of 
acute liver injury providing their stability is confirmed in each specific clinical study. When normalized 
by any of the stable miRNAs, miR-122-5p was superior to ALT. At first presentation, miR-122-5p was 
also superior to other miRNAs with regard to prediction of subsequent liver injury. This important result 
may reflect the high abundance of miR-122-5p within the hepatocyte compared to other miRNAs, its 
high degree of tissue selectivity, potential different pathways of release from injured cells (although miR-
885-5p is also bound to same protein), different stability in the circulation or miR-122-5p having a higher 
baseline circulating concentration. Interestingly, combining miR-122-5p with miR-483-3p resulted in 
an increase in predictive accuracy (as judged by the largest area under the ROC curve). While this is 
hypothesis generating, it may be that combining miRNAs that increase and decrease represents the opti-
mal biomarker qualification strategy.
In conclusion, miRNA panels are associated with liver and kidney toxicity in patients with acetami-
nophen overdose. These panels include novel miRNAs not previously described as toxicology biomark-
ers. For patient stratification at first presentation to hospital miR-122-5p is the lead miRNA candidate for 
clinical development, possibly in combination with miR-483-3p. Use of miRNA biomarkers could allow 
earlier prediction of patients at risk of organ injury and enable targeted intervention in these patients; 
furthermore they could allow earlier prediction of patients at low risk and enable shorter antidotal treat-
ment regimens and reduce length of hospital stay.
Patients and Methods
Patient Cohorts. The local research ethics committee approved the study and informed consent was 
obtained from all patients before entry into the study. The study was carried out in accordance with the 
approved relevant guidelines.
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Acetaminophen toxicity (APAP-TOX) patients. A total of 68 adult patients (aged 16 years and 
above) admitted to the Royal Infirmary of Edinburgh (RIE), UK with ALI, secondary to acetaminophen 
ingestion, were entered into the study. ALI was defined as a sudden deterioration in liver function in the 
absence of a history of chronic liver disease with a clear history of excess acetaminophen ingestion. All 
patients received intravenous NAC treatment.
There were two separate cohorts within this APAP-TOX group. First, patients admitted to the Clinical 
Toxicology Unit at RIE with a peak serum ALT activity greater than 3 x upper limit of normal (> 150 U/L) 
formed the training set (N = 27). Second, patients admitted to the Scottish Liver Transplantation Unit 
at RIE with peak ALT > 150 U/L formed the test set (N = 41). There was no patient overlap between 
training and test sets. Blood samples with peak hospital stay ALT activity were analysed in both training 
and test sets.
Acetaminophen no toxicity (APAP-no TOX) patients. 67 patients were recruited from RIE. The 
entry criterion was a history of acetaminophen ingestion in overdose that required treatment with NAC 
as per UK guidelines at the time of hospital admission24. All patients had a plasma acetaminophen con-
centration above the Prescott nomogram, which confirmed potentially toxic exposure. Blood was col-
lected at the end of the intravenous NAC infusion for measurement of serum ALT activity and absence 
of liver injury was confirmed by a normal serum ALT activity (< 50 U/L). APAP-no TOX patients were 
age- and sex-matched with the training and test set APAP-TOX patients. There was no patient overlap 
between training and test set. Blood from the end of NAC treatment was used in this study.
Acute liver injury not due to acetaminophen (Non-APAP ALI). Samples from 5 subjects with 
ALI not due to acetaminophen were recruited to this study. The causes of injury were autoimmune 
hepatitis, primary graft non-function, small-for-size syndrome, malignancy and clarithromycin-induced 
liver injury.
First presentation to hospital patients (APAP-early). These patients (total N = 67) were all 
recruited from St Thomas’ Hospital, London UK. Inclusion criteria were: adult with a clear history of 
excess acetaminophen ingestion and a timed blood acetaminophen concentration that was judged by the 
treating physician to necessitate hospital admission for intravenous NAC therapy, as per UK guidelines 
at the time of study. All patients completed the full course of NAC treatment. For all study participants, 
demographic data and blood results were recorded. ALI was defined as peak serum ALT activity greater 
than 3x the upper limit of the normal range (> 150 IU/L), the UK indication for continuing NAC therapy 
after completion of the initial regimen. The first blood sample at presentation to hospital was collected 
for the APAP-early cohort.
In all groups, blood samples were centrifuged at 1000 × g for 15 minutes at 4 °C. The supernatant was 
then separated into aliquots and stored at − 80 °C until analysis.
MicroRNA profiling of training set. In the training set 27 APAP-TOX samples were compared with 
27 APAP-no TOX samples. The methods for profiling are described in the supplemental methods.
MicroRNA profiling of test set. In the test set 41 APAP-TOX samples were compared with 40 
APAP-no TOX samples. miRNA species were selected based on fold change from the training set results. 
Sample processing was as described for the training set and real-time PCR was again performed on a 
Fluidigm BioMark HD.
Ago2-associated miRNA isolation. Magna Bind goat anti-mouse IgG magnetic bead slurry, 100 μ L, 
(Thermo Scientific, Waltham, USA) was incubated with 10 μ g of mouse monoclonal anti-Ago2 (Abcam, 
Cambridge, UK) or mouse normal IgG (Santa Cruz Biotechnology, Dallas, US) antibodies for 2 h at 4 °C. 
The antibody-coated beads were then added to plasma and incubated overnight at 4 °C with rotation. 
Beads were washed and each sample then eluted in RNAse free water before QIAzol was added for RNA 
isolation. Ago2 isolation was determined by western blot analysis.
Targeted miRNA measurement. Selected miRNAs were quantified in plasma samples by RT-qPCR 
as described in the supplemental methods. In situ hybridisation was performed on human liver removed 
at the time of transplantation (explant) using methods described in our previous study13. The patients 
had severe acute liver failure secondary to acetaminophen overdose.
Mouse models of liver and kidney toxicity. Mouse studies were in accordance the Animals 
(Scientific Procedures) Act 1986 and approved by the local Animal Ethics Committee. In brief, male CD1 
mice (28–33 g) were treated with either 0.9% saline, cisplatin (20 mg/kg) or acetaminophen (350 mg/kg) 
IP. At 24–72 hours after treatment, blood was collected via cardiac puncture and allowed to clot before 
isolation of serum which was stored at − 80 °C. Tissue samples were collected and either snap frozen or 
fixed in neutral buffered formalin (10%).
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Statistical analysis. Data are presented as median and range or interquartile range (IQR). Each 
dataset was analysed for normality using a Shapiro-Wilk test. For nonparametric datasets, comparisons 
were made using the Mann-Whitney U test or Wilcoxon matched-pairs signed rank test. All calcula-
tions and receiver operator characteristic (ROC) curves were performed using GraphPad Prism software 
(GraphPad Software, La Jolla, CA). Profiling data were analysed by random forests to give an estimate 
of how well we can classify individuals in a new data set into each group. Random forests create a set of 
classification trees based on continual sampling of the experimental units and compounds. Each obser-
vation is then classified based on the majority votes from all of the classification trees. Details of random 
forest analysis can be found in the supplemental methods.
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